The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Copper is required for oncogenic BRAF signalling and tumorigenesis
Open accessAbstract
The BRAF kinase is mutated, typically Val 600→Glu (V600E), to induce an active oncogenic state in a large fraction of melanomas, thyroid cancers, hairy cell leukaemias and, to a smaller extent, a wide spectrum of other cancers. BRAFV600E phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate and activate the ERK1 and ERK2 kinases, stimulating the mitogen-activated protein kinase (MAPK) pathway to promote cancer. Targeting MEK1/2 is proving to be an important therapeutic strategy, given that a MEK1/2 inhibitor provides a survival advantage in metastatic melanoma, an effect that is increased when administered together with a BRAFV600E inhibitor. We previously found that copper (Cu) influx enhances MEK1 phosphorylation of ERK1/2 through a Cu–MEK1 interaction. Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAFV600E-driven signalling and tumorigenesis in mice and human cell settings. Conversely, a MEK1–MEK5 chimaera that phosphorylated ERK1/2 independently of Cu or an active ERK2 restored the tumour growth of murine cells lacking Ctr1. Cu chelators used in the treatment of Wilson disease decreased tumour growth of human or murine cells transformed by BRAFV600E or engineered to be resistant to BRAF inhibition. Taken together, these results suggest that Cu-chelation therapy could be repurposed to treat cancers containing the BRAFV600E mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
How to study proteins by circular dichroism
Kelly, S. M., Jess, T. J., & Price, N. C. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.06.005 · Cited by 3,351
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Rappsilber, J., Ishihama, Y., & Mann, M. (2003) · Analytical Chemistry · doi:10.1021/ac026117i · Cited by 2,644
Niesen, F. H., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,408
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“While the detailed mechanism underlying the requirement of Cu for robust MEK1/2 kinase activity remains to be elucidated, we show that decreasing Cu influx, Cu bioavailability, and binding of Cu to MEK1 reduced MEK1(2) kinase activity and oncogenic BRAF-driven tumorigenesis.”
BackgroundImproved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Ala, A., Walker, A. P., Ashkan, K., Dooley, J. S., & Schilsky, M. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60196-2 · Cited by 1,446
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
Nobles, K. N., Xiao, K., Ahn, S., Shukla, A. K., Lam, C. M., Rajagopal, S., Strachan, R. T., Huang, T.-Y., Bressler, E. A., Hara, M. R., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001707 · Cited by 626
Self-citationIntegrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene
Boehm, J. S., Zhao, J. J., Yao, J., Kim, S. Y., Firestein, R., Dunn, I. F., Sjostrom, S. K., Garraway, L. A., Weremowicz, S., Richardson, A. L., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.052 · Cited by 617
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481
Chu, Y., Solski, P. A., Khosravi-Far, R., Der, C. J., & Kelly, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.6497 · Cited by 442
Distinct requirements for Ras oncogenesis in human versus mouse cells
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M. (2002) · Genes & Development · doi:10.1101/gad.993902 · Cited by 431
Self-citationNew Roles for Copper Metabolism in Cell Proliferation, Signaling, and Disease
Turski, M. L., & Thiele, D. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800055200 · Cited by 422
Self-citationPuig, S., Lee, J., Lau, M., & Thiele, D. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202547200 · Cited by 396
Self-citationDooley, J. S., & Ala, A. (2010) · Evidence‐Based Gastroenterology and Hepatology · doi:10.1002/9781444314403.ch31 · Cited by 386
Nose, Y., Kim, B.-E., & Thiele, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.08.009 · Cited by 325
Self-citationA Novel Role for Copper in Ras/Mitogen-Activated Protein Kinase Signaling
Turski, M. L., Brady, D. C., Kim, H. J., Kim, B.-E., Nose, Y., Counter, C. M., Winge, D. R., & Thiele, D. J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.05722-11 · Cited by 320
Self-citationOptimization and Use of Peptide Mass Measurement Accuracy in Shotgun Proteomics
Haas, W., Faherty, B. K., Gerber, S. A., Elias, J. E., Beausoleil, S. A., Bakalarski, C. E., Li, X., Villén, J., & Gygi, S. P. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500339-mcp200 · Cited by 261
Multiple ligand-specific conformations of the β2-adrenergic receptor
Kahsai, A. W., Xiao, K., Rajagopal, S., Ahn, S., Shukla, A. K., Sun, J., Oas, T. G., & Lefkowitz, R. J. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.634 · Cited by 250
Self-citationCharacterization of Mouse Embryonic Cells Deficient in the Ctr1 High Affinity Copper Transporter
Lee, J., Petris, M. J., & Thiele, D. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208002200 · Cited by 244
Self-citationResistance to BRAF Inhibition in Melanomas
Solit, D. B., & Rosen, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmcibr1013704 · Cited by 243
Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors
Fischmann, T. O., Smith, C. K., Mayhood, T. W., Myers, J. E., Reichert, P., Mannarino, A., Carr, D., Zhu, H., Wong, J., Yang, R.-S., et al. (2009) · Biochemistry · doi:10.1021/bi801898e · Cited by 183
Bric, A., Miething, C., Bialucha, C. U., Scuoppo, C., Zender, L., Krasnitz, A., Xuan, Z., Zuber, J., Wigler, M., Hicks, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.015 · Cited by 161
Bertinato, J., & L’Abbé, M. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302242200 · Cited by 160
Biochemical and biological analysis of Mek1 phosphorylation site mutants.
Huang, W., Kessler, D. S., & Erikson, R. L. (1995) · Molecular Biology of the Cell · doi:10.1091/mbc.6.3.237 · Cited by 131
Contribution of the ERK5/MEK5 Pathway to Ras/Raf Signaling and Growth Control
English, J. M., Pearson, G. W., Hockenberry, T., Shivakumar, L., White, M. A., & Cobb, M. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.44.31588 · Cited by 129
Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling
Tsai, C., Finley, J. C., Ali, S. S., Patel, H. H., & Howell, S. B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.014 · Cited by 93
Targeting eNOS in Pancreatic Cancer
Lampson, B. L., Kendall, S. D., Ancrile, B. B., Morrison, M. M., Shealy, M. J., Barrientos, K. S., Crowe, M. S., Kashatus, D. F., White, R. R., Gurley, S. B., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0057 · Cited by 74
Self-citationMek1 Alters Epidermal Growth and Differentiation
Scholl, F. A., Dumesic, P. A., & Khavari, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0017 · Cited by 73
Levin‐Salomon, V., Kogan, K., Ahn, N. G., Livnah, O., & Engelberg, D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806443200 · Cited by 65
Bridgewater, J. D., & Vachet, R. W. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.02.034 · Cited by 59
A Genetically Defined Normal Human Somatic Cell System to Study Ras Oncogenesis In Vivo and In Vitro
O’Hayer, K., & Counter, C. M. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)07050-3 · Cited by 56
Self-citationNakamura, K., Uhlik, M. T., Johnson, N. L., Hahn, K. M., & Johnson, G. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2065-2079.2006 · Cited by 53
Ral activation promotes melanomagenesis
Zipfel, P. A., Brady, D. C., Kashatus, D. F., Ancrile, B. D., Tyler, D. S., & Counter, C. M. (2010) · Oncogene · doi:10.1038/onc.2010.224 · Cited by 47
Self-citationSorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Augustine, C. K., Toshimitsu, H., Jung, S., Zipfel, P. A., Yoo, J. S., Yoshimoto, Y., Selim, M. A., Burchette, J. L., Beasley, G. M., McMahon, N. S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0073 · Cited by 45
ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis
O’Hayer, K., Brady, D. C., & Counter, C. M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp198 · Cited by 37
Self-citation
Cited by
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Copper homeostasis and cuproptosis in health and disease
Chen, L., Min, J., & Wang, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01229-y · Cited by 1,493
Connecting copper and cancer: from transition metal signalling to metalloplasia
Ge, E. J., Bush, A. I., Casini, A., Cobine, P. A., Cross, J. R., DeNicola, G. M., Dou, Q. P., Franz, K. J., Gohil, V. M., Gupta, S., et al. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00417-2 · Cited by 1,298
Self-citationTargeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Targeting copper in cancer therapy: ‘Copper That Cancer’
Denoyer, D., Masaldan, S., La Fontaine, S., & Cater, M. A. (2015) · Metallomics · doi:10.1039/c5mt00149h · Cited by 806
Metadata
- Authors
- Brady, D. C., Crowe, M. S., Turski, M. L., Hobbs, G. A., Yao, X., Chaikuad, A., Knapp, S., Xiao, K., Campbell, S. L., Thiele, D. J., & Counter, C. M.
- Venue
- Nature
- Published
- 2014-04-09
- Volume
- 509
- Issue
- 7501
- Pages
- 492-496
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014912105
- Cited by
- 609
- References
- 43
- FWCI
- 15.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.